Application of licochalcone in preparation of anti-hepatoma drug and anti-hepatoma drug

By using licorice ceramide chalkone to inhibit the growth and migration of liver cancer cells, the problems of low efficiency and great toxic and side effects of existing liver cancer treatment drugs are solved, and a safe and efficient anti-hepatitis cancer drug is provided, filling the gap in the lack of evidence for traditional Chinese medicine treatment. .

CN118903074APending Publication Date: 2024-11-08重庆医科大学国际体外诊断研究院
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411029324.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-30
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Existing liver cancer treatment drugs are inefficient and have great toxic and side effects. Traditional Chinese medicine treatment lacks high-level evidence-based medical evidence, and the mechanism of action of traditional Chinese medicine extracts is unclear, making it difficult to provide more effective anti-hepatitis cancer methods.

Method used

Using licorice charcoalone as the active ingredient, downregulates the expression of related proteins by inhibiting the growth, migration and cell cycle of liver cancer cells, affecting the MAPK signaling pathway, and prepares anti-hepatic cancer drugs, including dosage forms such as granules, tablets, and capsules.

Benefits of technology

Licorice charone significantly inhibits the growth of liver cancer cells, has good drug safety, and does not cause obvious pathological damage to healthy mice, providing more efficient anti-hepatitis cancer treatment methods.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004969485640000021
    Figure BDA0004969485640000021
  • Figure FDA0004969485630000011
    Figure FDA0004969485630000011
  • Figure HDA0004969485650000011
    Figure HDA0004969485650000011
Patent Text Reader

Abstract

The invention relates to the technical field of medicines, in particular to application of licochalcone in preparation of an anti-liver cancer drug and the anti-liver cancer drug. The licochalcone provided by the invention has a certain inhibition effect on human-derived liver cancer in vivo and in vitro, and can significantly inhibit the growth of liver cancer cells, the specific mechanism is that the cell cycle is retarded in S period and G2 / M period and / or the expression of related proteins of the liver cancer cell cycle is reduced, and the specific related proteins are CyclinA and / or CDK2 and / or CyclinB1 and / or Phospho-FistoneH3. The licochalcone can inhibit liver cancer cell migration, and the specific mechanism is realized in a mode of down-regulating the expression of Snail, Vimentin, N-cadherin, MMP2, MMP7 and MMP9. In addition, the licochalcone can inhibit a potential signal channel of the cell viability of the liver cancer, particularly an MAPK signal channel, and by up-regulating the expression of p-JNK and p-p38, the licochalcone has good drug safety.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of medicines, and in particular to application of licorice chalcone in the preparation of anti-liver cancer drugs and the anti-liver cancer drugs. Background Art

[0002] Primary liver cancer is one of the most common malignant tumors in clinical practice. According to histological analysis, most liver cancers (75-85%) are primary liver cancers. The high incidence and mortality of liver cancer bring huge economic burden to society. Therefore, exploring effective treatment options for liver cancer is still a clinical problem that needs to be solved urgently.

[0003] At present, the treatment options for liver cancer mainly include surgical treatment and non-surgical treatment. Although surgical treatment is the most effective method for treating primary liver cancer, most patients have reached the middle and late stages or have distant metastases when diagnosed due to the insidious onset of primary liver cancer, asymptomatic or unclear symptoms in the early stage, and lose the opportunity for surgery. Therefore, systemic drug therapy plays an important role in the treatment of liver cancer. Liver cancer treatment drugs include molecular targeted drugs (sorafenib) and traditional cytotoxic drugs (doxorubicin, cisplatin, fluorouracil, etc.), but sorafenib is only effective for some patients, and traditional cytotoxic drugs are not effective and have large toxic side effects. As an important part of the comprehensive treatment of liver cancer, natural product therapy has played a unique advantage in preventing the occurrence of liver cancer, reducing recurrence, improving the quality of life and prolonging survival. However, in general, Chinese medicine treatment has many targets, complex drug ingredients, and difficult to clarify mechanisms, and lacks high-level evidence-based medicine to fully support and prove its role. Chinese herbal extracts can not only give full play to the advantages of low toxicity and good tolerance of Chinese medicine, but also combine modern discipline theory, clinical practice foundation and perfect experimental methods. Therefore, it is of great clinical significance to screen out more effective active ingredients from traditional Chinese medicine and explore the anti-liver cancer effects of traditional Chinese medicine extracts and their specific anti-cancer mechanisms, which can provide more effective means for the comprehensive treatment of liver cancer. Summary of the invention

[0004] In view of this, the purpose of the present invention is to provide the use of licorice chalcone in the preparation of anti-liver cancer drugs and the anti-liver cancer drugs, and licorice chalcone can significantly inhibit the growth of liver cancer cells.

[0005] The present invention solves the above technical problems by the following technical means:

[0006] In a first aspect, the present invention provides the use of Glycyrrhiza uralensis chalcone in the preparation of anti-liver cancer drugs.

[0007] In combination with the first aspect, in some embodiments, the chemical structural formula of the licorice chalcone is as follows:

[0008]

[0009] In a second aspect, the present invention provides an anti-liver cancer drug comprising Glycyrrhiza uralensis chalcone as an active ingredient and a pharmaceutically acceptable carrier or excipient.

[0010] In combination with the second aspect, in some embodiments, the dosage form of the anti-liver cancer drug is granules, tablets, capsules, pills, suspensions, injections, oral solutions or infusions.

[0011] The present invention provides the application of licorice chalcone in the preparation of anti-liver cancer drugs, and anti-liver cancer drugs containing licorice chalcone. According to experiments, licorice chalcone (Ecn) has a certain inhibitory effect on human liver cancer in vivo and in vitro, and can significantly inhibit the growth of liver cancer cells. The specific mechanism is to block the cell cycle in the S phase and G2 / M phase and / or down-regulate the expression of liver cancer cell cycle-related proteins. The specific related proteins are CyclinA and / or CDK2 and / or CyclinB1 and / or Phospho-FistoneH3. According to experiments, licorice chalcone can inhibit the migration of liver cancer cells. The specific mechanism is to down-regulate the expression of Snail, Vimentin, N-cadherin, MMP2, MMP7 and MMP9. Licorice chalcone can also inhibit the potential signal pathway of liver cancer cell activity, specifically the MAPK signal pathway, and by up-regulating the expression of p-JNK and p-p38.

[0012] In addition, experiments have shown that Glycyrrhiza uralensis chalcone did not cause obvious pathological damage to the liver, heart, kidney and lung of all tumor mice, and Glycyrrhiza uralensis chalcone had no significant effect on the body weight, blood routine, biochemical indicators and organ sections of healthy mice, indicating that it has good drug safety. BRIEF DESCRIPTION OF THE DRAWINGS

[0013] Figure 1 It is the chemical formula of Licorice Chalcone;

[0014] Figure 2 The results of crystal violet test and MTT test of the inhibitory effect of licorice chalcone on the growth of human hepatoma cell lines;

[0015] Figure 3 This is the result of the clone formation test of the growth inhibition effect of Licorice Chalcone on human hepatoma cell lines;

[0016] Figure 4 This is the test result of the effect of Licorice Chalcone on the expression of proteins related to the proliferation of liver cancer cells;

[0017] Figure 5 This is the test result of Licorice Chalcone blocking the liver cancer cell cycle;

[0018] Figure 6This is the test result of Licorice Chalcone down-regulating the expression of liver cancer cell cycle-related proteins;

[0019] Figure 7 This is a test result of the effect of licorice chalcone on the migration ability of liver cancer cell lines;

[0020] Figure 8 This is a test result of the effect of Licorice Chalcone on the invasion ability of liver cancer cell lines;

[0021] Fig. 9 This is the test result of the effect of Glycyrrhiza uralensis chalcone on the expression of proteins related to liver cancer cell migration;

[0022] Fig.10 This is a graph showing the test results of the protein expression related to the mechanism of Glycyrrhiza uralensis chalcone affecting the activity of liver cancer cells;

[0023] Fig.11 This is a test result of the inhibitory effect of Glycyrrhiza uralensis chalcone on the weight of nude mouse transplanted tumors;

[0024] Fig.12 This is the result of HE staining test of Glycyrrhiza uralensis chalcone on nude mouse transplanted tumor sections;

[0025] Fig.13 This is the result of IHC staining test of Glycyrrhiza uralensis chalcone on nude mouse transplanted tumor sections;

[0026] Fig.14 This is a test result of the effect of Glycyrrhiza uralensis chalcone on the HE staining of the heart, kidney, liver and lung sections of the nude mouse transplanted tumor model;

[0027] Fig.15 This is the test result of glycyrrhiza uralensis chalcone being administered to healthy mice orally, and there was no significant change in body weight, blood routine, biochemical indexes and organ sections. DETAILED DESCRIPTION

[0028] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0029] In the following examples, if no specific conditions are specified, the experiments were carried out under conventional conditions or conditions recommended by the manufacturer. The raw materials, equipment or instruments used, if no manufacturer is specified, are all conventional products that can be purchased on the market.

[0030] The words “include,” “including,” “have,” “contain,” etc. used in this document are open-ended terms, meaning including but not limited to.

[0031] The present invention discloses the application of licorice chalcone in the preparation of anti-liver cancer drugs and the anti-liver cancer drugs. The chemical structural formula of licorice chalcone can be found in Figure 1 . Licorice chalcone has a certain inhibitory effect on human liver cancer both in vivo and in vitro, and can significantly inhibit the growth of liver cancer cells. The specific mechanism is to block the cell cycle in the S phase and G2 / M phase and / or downregulate the expression of liver cancer cell cycle-related proteins. The specific related proteins are CyclinA and / or CDK2 and / or CyclinB1 and / or Phospho-FistoneH3. Licorice chalcone can inhibit the migration of liver cancer cells. The specific mechanism is to downregulate the expression of Snail, Vimentin, N-cadherin, MMP2, MMP7 and MMP9. Licorice chalcone can also inhibit the potential signaling pathway of liver cancer cell activity, specifically the MAPK signaling pathway, and upregulate the expression of p-JNK and p-p38. In addition, Licorice chalcone has good drug safety.

[0032] For details, please refer to Examples 1-9:

[0033] HepG2 and Huh-7 cells were obtained from the Key Laboratory of Medical Laboratory Science of Chongqing Medical University.

[0034] Source of Ecn (Ecn): purchased from Sichuan Cuiyirun Biotechnology Co., Ltd., item number: CYR-C0021.

[0035] HCC cells refer to liver cancer cells HepG2 and Huh-7; nude mice were purchased from Changzhou Cavens Experimental Animal Co., Ltd.

[0036] Example 1

[0037] This example studies the inhibitory effect and mechanism of licorice chalcone on the growth of liver cancer cell lines, as follows:

[0038] HepG2 and Huh-7 cells were seeded into 24-well plates using the crystal violet method. When the cell density reached 2.5 × 10 4 When cells / well were measured, cells were treated with different concentrations of Ecn (0, 10, 15, 20 and 25 μM), and fixed with 4% paraformaldehyde for 10 minutes at 24 hours, 48 ​​hours and 72 hours after treatment, and then stained with crystal violet. For quantification, 200 μL of 10% glacial acetic acid was used to dissolve crystal violet, and the absorbance of each well was measured at a wavelength of 570 nm using a multifunctional microplate reader. The experimental results are shown in Figure 2 shown.

[0039] HepG2 and Huh-7 cells were cultured at 2.5 × 10 3The cells were inoculated into 96-well plates at a density of 100 μM / well and then treated with different concentrations of Ecn (0, 10, 15, 20 and 25 μM). 24 hours, 48 ​​hours and 72 hours after treatment, the cells were incubated with MTT solution (5 mg / mL, 10 μL / well) at 37 degrees Celsius for 4 hours, and then dimethyl sulfoxide (DMSO) (100 μL / well) was added to completely dissolve the MTT crystals. The cell plate was then placed in a multifunctional microplate reader to detect the absorbance at a wavelength of 492 nanometers. The experimental results are shown in Figure 2. Figure 2 shown.

[0040] Through clone formation experiments, HepG2 and Huh-7 cells were cultured at 7×10 2 The cells were seeded into 6-well plates at a density of 100 μM / well. Then, the cells were treated with different concentrations of Ecn (0, 10, 15, and 20 μM) and cultured continuously. When visible colonies formed in the 0 μM group, all treated cell cultures were terminated. The cells were rinsed with PBS, fixed with 4% paraformaldehyde for 10 minutes, and then stained with crystal violet to observe the formed colonies. Colonies containing more than 50 cells were considered valid colonies, and the number of valid colonies was calculated using ImageJ software. The experimental results are shown in Figure 2. Figure 3 shown.

[0041] Figure 2 and Figure 3 The data showed that Glycyrrhiza uralensis chalcone had a certain inhibitory effect on the growth of HepG2 and Huh-7 cells, and the inhibitory effect increased with the increase of Glycyrrhiza uralensis chalcone concentration.

[0042] Example 2

[0043] This example studies the effect of licorice chalcone on down-regulating the expression of proteins related to liver cancer cell proliferation, as follows:

[0044] HCC cells were treated with different concentrations (0, 10, 15 and 20 μM) of Ecn for 24 hours, and then the cells were lysed with RIPA lysis buffer containing phosphatase inhibitors to extract total intracellular protein. The protein samples were separated by SDS-PAGE and transferred to a polyvinylidene fluoride (PVDF) membrane. After blocking with 5% BSA for 2 hours at room temperature, incubated with the corresponding primary antibody (1:1000 dilution) at 4°C overnight. The membrane was washed three times with TBST and then incubated with the corresponding horseradish peroxidase-conjugated secondary antibody (1:5000 dilution) at 37°C for 1 hour. The membrane was washed again, the protein bands were detected with an ECL kit, and the gel imaging system was used to take pictures. The experimental results are shown in the figure. Figure 4 shown.

[0045] Figure 4The data showed that after treatment with Glycyrrhiza uralensis chalcone, the protein expressions of proliferation-related proteins PCNA and c-Myc in HepG2 and Huh-7 cells were significantly decreased, and the inhibitory effect increased with the increase of Glycyrrhiza uralensis chalcone concentration.

[0046] Example 3

[0047] This example studies the blocking of liver cancer cell cycle by licorice chalcone, as follows:

[0048] HCC cells were seeded into 6-well plates, and when the cell density reached approximately 30% confluence, the cells were treated with different concentrations (0, 10, 15, and 20 μM) of Ecn for 24 h. To evaluate cell apoptosis, the cells were rinsed three times with PBS, stained with AnnexinV-FITC / PI solution, and then immediately analyzed by flow cytometry. To determine the cell cycle distribution, the cells were fixed with 500 μL of 75% ethanol at 4 °C overnight, stained with PI solution, and then analyzed by flow cytometry. The experimental results are shown in Figure 2. Figure 5 shown.

[0049] Figure 5 The data showed that after treatment with licorice chalcone, HepG2 cells arrested in the S phase and Huh-7 cells arrested in the G2 / M phase.

[0050] Example 4

[0051] This example studies the effect of licorice chalcone on down-regulating the expression of liver cancer cell cycle-related proteins, as follows:

[0052] HCC cells were treated with different concentrations (0, 10, 15 and 20 μM) of Ecn for 24 hours, and then the cells were lysed with RIPA lysis buffer containing phosphatase inhibitors to extract total intracellular protein. The protein samples were separated by SDS-PAGE and transferred to a polyvinylidene fluoride (PVDF) membrane. After blocking with 5% BSA for 2 hours at room temperature, incubated with the corresponding primary antibody (1:1000 dilution) at 4°C overnight. The membrane was washed three times with TBST and then incubated with the corresponding horseradish peroxidase-conjugated secondary antibody (1:5000 dilution) at 37°C for 1 hour. The membrane was washed again, the protein bands were detected with an ECL kit, and the gel imaging system was used to take pictures. The experimental results are shown in the figure. Figure 6 shown.

[0053] Figure 6 The data showed that after Ecn treatment, the protein levels of S phase-related regulators CyclinA and CDK2 in HepG2 cells and the protein and level of G2 / M phase-related regulator CyclinB1 in Huh-7 were decreased, indicating that Ecn can inhibit the proliferation of HCC cells and induce cell cycle arrest.

[0054] Example 5

[0055] This example studies the effect and mechanism of licorice chalcone on reducing the migration ability of liver cancer cell lines, as follows:

[0056] Transwell assay was used to evaluate cell migration and invasion. For cell invasion analysis, 2.5 × 10 cells were cultured in 400 μL serum-free DMEM medium in the upper chamber coated with 20-fold diluted Matrigel. 4 HCC cells were added to the lower chamber, and 500 μL of DMEM culture medium containing different concentrations (0, 10, 15 and 20 μM) of Ecn was added. After culturing for 24 hours, the non-invading cells on the upper part of the upper chamber were removed with a cotton swab. The invading cells on the outside of the upper chamber were fixed with 4% formaldehyde for 10 minutes, stained with crystal violet, and then photographed under an optical microscope. The steps of the migration assay were actually the same as the invasion analysis, except that the upper chamber was not coated with Matrigel, and HCC cells were seeded into a 6-well plate. When the cells reached nearly 90%, a sterile 10 μL pipette was used to create linear artificial wounds in a direction perpendicular to the cell layer. After gently washing the cells with PBS, they were cultured with fresh DMEM containing different concentrations (0, 10, 15 and 20 μM) of Ecn for 12 hours and 24 hours, respectively. At the specified time points, each wound was randomly photographed and measured using ImageJ software. The experimental results are shown in Figure 7 and Figure 8 shown.

[0057] Figure 7 and Figure 8 The data showed that Glycyrrhiza uralensis chalcone had an inhibitory effect on the migration and invasion of liver cancer cell lines HepG2 and Huh-7, and the inhibitory effect increased with the increase of Glycyrrhiza uralensis chalcone concentration.

[0058] Example 6

[0059] This example studies the effect of licorice chalcone on the expression of proteins related to liver cancer cell migration, as follows:

[0060] HCC cells were treated with different concentrations of Ecn (0, 10, 15 and 20 μM) for 24 hours, and then the cells were lysed with RIPA lysis buffer containing phosphatase inhibitors to extract total intracellular protein. The protein samples were separated by SDS-PAGE and transferred to a polyvinylidene fluoride (PVDF) membrane. After blocking with 5% BSA for 2 hours at room temperature, the membrane was incubated with the corresponding primary antibody (1:1000 dilution) at 4°C overnight. The membrane was washed three times with TBST and then incubated with the corresponding horseradish peroxidase-conjugated secondary antibody (1:5000 dilution) at 37°C for 1 hour. The membrane was washed again, the protein bands were detected with an ECL kit, and the gel imaging system was used to take pictures. The experimental results are shown in Figure 2. Fig. 9 shown.

[0061] Fig. 9 The data showed that after treatment with Glycyrrhiza uralensis chalcone, the expressions of cell cycle-related proteins Snail, Vimentin, N-cadherin, MMP2, MMP7 and MMP9 in HepG2 and Huh-7 cells were significantly decreased, and the regulatory effects increased with the increase of Glycyrrhiza uralensis chalcone concentration.

[0062] Example 7

[0063] This example studies the up-regulation of JNK / P38MAPK pathway signaling pathway-related protein expression in liver cancer cells by licorice chalcone, as follows:

[0064] HCC cells were treated with different concentrations (0, 10, 15 and 20 μM) of Ecn for 24 hours, and then the cells were lysed with RIPA lysis buffer containing phosphatase inhibitors to extract total intracellular protein. The protein samples were separated by SDS-PAGE and transferred to a polyvinylidene fluoride (PVDF) membrane. After blocking with 5% BSA for 2 hours at room temperature, incubated with the corresponding primary antibody (1:1000 dilution) at 4°C overnight. The membrane was washed three times with TBST and then incubated with the corresponding horseradish peroxidase-conjugated secondary antibody (1:5000 dilution) at 37°C for 1 hour. The membrane was washed again, the protein bands were detected with an ECL kit, and the gel imaging system was used to take pictures. The experimental results are shown in the figure. Fig.10 shown.

[0065] Fig.10 The data showed that phosphorylation of p38 (p-p38) and JNK (p-JNK) in both cell lines was significantly increased after treatment with licorice chalcone, while total p38 and JNK proteins remained unchanged.

[0066] Example 8

[0067] This example studies the in vitro anti-liver cancer effect of Glycyrrhiza uralensis chalcone, as follows:

[0068] Mouse subcutaneous tumor model experiment: Female BALB / C athymic immunodeficient nude mice of about 4 weeks old were selected and raised in the IVC system of the SPF animal room for 7 days to observe their growth status. HepG2 cells (4×107) were suspended in 60 μl of sterile PBS and subcutaneously injected into the right abdomen of female BALB / c nude mice (4 weeks old) to establish a xenograft tumor model. To determine the inhibitory effect of a single dose of SEC on the growth of BC cell xenograft tumors, mice were randomly divided into the following five groups (3 mice / group): carboxymethyl cellulose (CMC) group, 0 mg / kg SEC group, 20 mg / kg SEC group, 40 mg / kg SEC group and 60 mg / kg SEC group. Mice were gavaged with different doses of SEC (0 mg / kg, 20 mg / kg, 40 mg / kg and 60 mg / kg) or 0.5% CMC every two days for a total of 10 consecutive gavages, and the body weight and tumor volume of each group were recorded. After the experiment, all mice were killed by cervical dislocation. Tumor tissue, liver and kidney tissue were collected for fixation, paraffin embedding and sectioning. Fig.11 , Fig.12 , Fig.13 , Fig.14 .

[0069] Fig.11 The data showed that the volume of nude mouse transplanted tumors was significantly reduced after treatment with Ecn compared with the control group; H&E staining showed that the CMC group showed obvious malignant phenotypes, such as tight cell arrangement, dark nuclear staining, and imbalanced nuclear-cytoplasmic ratio. However, these malignant phenotypes were significantly weakened after Ecn treatment (see Fig.12 ). Consistent with the Western blot results, IHC staining results showed that Ecn decreased the levels of PCNA, MMP2, and Vimentin proteins, while increasing the levels of p-p38 and p-JNK (see Fig.13 ). The above results indicate that Ecn can inhibit the xenograft tumor growth of HCC cells in vivo. It is noteworthy that no obvious pathological damage was caused to the liver, heart, kidney, and lung of all tumor-bearing mice, indicating that the toxicity of Ecn in vivo is very low (see Fig.14 ).

[0070] Example 9

[0071] This example studies the toxicity of Glycyrrhiza uralensis chalcone in vivo, as follows:

[0072] The in vivo toxicity of Ecn was evaluated in immunocompetent BALB / c mice. BALB / c mice (female, 4 weeks old) were divided into the following 5 groups (3 mice in each group): CMC group, 0 mg / kg Ecn group, 20 mg / kg Ecn group, 40 mg / kg Ecn group and 60 mg / kg Ecn group. Mice were gavaged with Ecn or carboxymethyl cellulose (CMC) once every two days for a total of 15 consecutive gavages. Subsequently, all mice were killed by cervical dislocation. Blood was collected from the orbits and routine blood tests were performed using an automatic blood analyzer (Sysmex, XT-2000i). When measuring biochemical indicators, serum was separated and the levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT) and blood urea nitrogen (BUN) were detected using an automatic biochemical analyzer (IDEXX Laboratories, Inc, Westbrook, ME, USA). At the same time, the kidney and liver tissues of each group were sectioned and stained with H&E to observe the histological structure. Mouse subcutaneous tumor model experiment: Female BALB / C athymic immunodeficient nude mice about 4 weeks old were raised in the IVC system of SPF animal room for 7 days and their growth was observed. HepG2 cells (4×10 7 ) were suspended in 60 μl of sterile PBS and injected subcutaneously into the right abdomen of female BALB / c nude mice (4 weeks old) to establish a xenograft tumor model. To determine the inhibitory effect of a single dose of SEC on the growth of BC cell xenograft tumors, the mice were randomly divided into the following five groups (3 mice / group): carboxymethyl cellulose (CMC) group, 0 mg / kg SEC group, 20 mg / kg SEC group, 40 mg / kg SEC group and 60 mg / kg SEC group. The mice were gavaged with different doses of SEC (0 mg / kg, 20 mg / kg, 40 mg / kg and 60 mg / kg) or 0.5% CMC every two days for a total of 10 consecutive gavages, and the body weight and tumor volume of each group were recorded. After the experiment, all mice were killed by cervical dislocation. Tumor tissues and kidney tissues were collected for HE staining. The experimental results are shown in the figure. Fig.15 shown.

[0073] Fig.15 The data showed that Glycyrrhiza uralensis chalcone had no significant effect on the body weight, blood routine, biochemical indexes and organ sections of healthy mice, indicating that it has good drug safety.

[0074] In summary, the licorice chalcone has an anti-liver cancer effect and can be used in the preparation of an anti-liver cancer drug. The anti-liver cancer drug comprises the licorice chalcone as an active ingredient and a pharmaceutically acceptable carrier or excipient. The dosage form of the anti-liver cancer drug is granules, tablets, capsules, pills, suspensions, injections, oral solutions or infusions.

[0075] The above embodiments are only used to illustrate the technical solutions of the present invention and are not intended to limit the present invention. Although the present invention is described in detail with reference to the preferred embodiments, it should be understood by those skilled in the art that the technical solutions of the present invention may be modified or replaced by equivalents without departing from the purpose and scope of the technical solutions of the present invention, which should be included in the scope of the claims of the present invention. The techniques, shapes, and structural parts not described in detail in the present invention are all known technologies.

Claims

1. Application of Glycyrrhiza uralensis chalcone in the preparation of anti-liver cancer drugs.

2. The use of the licorice chalcone according to claim 1 in the preparation of anti-liver cancer drugs, It is characterized in that The chemical structural formula of the licorice chalcone is as follows:

3. An anti-liver cancer drug, It is characterized in that The invention comprises licorice chalcone as an active ingredient and a pharmaceutically acceptable carrier or excipient.

4. The anti-liver cancer drug according to claim 3, It is characterized in that The dosage form of the anti-liver cancer drug is granules, tablets, capsules, pills, suspensions, injections, oral solutions or infusions.